Rocket Pharmaceuticals Long Term Debt

As of the most recent data (June 2026), RCKT shows a long-term debt of $22M. That compares with $22M in the prior-year period — down 2.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RCKT's long-term debt is now $22M (was $22M) — a 2.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Rocket Pharmaceuticals is outperforming or lagging.

Tracking RCKT's long-term debt over time shows whether Rocket Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $22M That compares with $22M in the prior-year period — down 2.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Rocket Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $22M) with ownership activity and broader fundamentals.

Rocket Pharmaceuticals's long-term debt is $22M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.